会议目录

中文信息

会议基本信息:

会议名称: 第五届ADC药物开发峰会

会议地点: 北京,中国

会议时间: 2023年3月1-2日

会议背景

截止到2023年10月,全世界范围内共有15款ADC药物获批上市。尤其是从2018年至今,在科研单位及行业的努力下,ADC药物的临床疗效取得了重大进展,以Enhertu为代表的ADC逐渐显示出成为10亿美元重磅炸弹的药品趋势,年复合增长率已经达到了40.4%。创新的偶联技术平台,优化的DARs值,改进的linker可以进一步的控制ADC的精准性、临床疗效、以及减少毒素副作用。在此背景下,中国的ADC药物开发也成功的吸引了全世界的目标,投资,授权合作不断。为此,我们将于2024年3月1-2日在北京,召开第五届ADC药物开发峰会。期待大家的出席!

image.png

会议主题:

 

M(主论坛). 全球ADC市场动态:投资与合作趋势

ADC药物开发走进舞台中央

中国ADC药物合作开发,国际大药厂押注下一个重磅炸弹赛道

ADC兼并,收购,合作的背后驱动力

A1. 靶点发现、转化医学及临床前开发

创新靶点及生物标志物验证

ADC非临床研究要点:药理学、毒理学、安全性评价要点

监管视角:ADC非临床开发挑战

可验证的端到端的ADC药物发现平台

避免热点靶点内卷、ADC开发的热门方向

A2: 临床开发:全球化及肿瘤以外适应症探索

全球化多中心临床的开发挑战

差异化临床开发: 临床策略提升ADC成功率

ADC联合治疗方向:与化疗Combo,

超越肿瘤及血液瘤:ADC实体瘤进展与非肿瘤适应症开发

简化临床开发,加速推动候选分子从实验室迈向临床

A3: 下一代创新偶联治疗实体

新型作用机制下的新型有效负载:超越传统毒素

不断创新的新型偶联治疗实体

推动XDC进入临床:创新设计以及控制开发风险

创新偶联治疗实体分享:蛋白降解偶联 / 多肽偶联 / 双抗偶联 / 双环肽的放射性偶联 等等

B1: 携手共进:MNC & 本土Biotech合作

ADC药物更广泛的治疗窗口挑战

MNC与中国本土创新Biotech管线合作开发,开发进展协同挑战

全球ADC药物开发背景下的中国机会

下一步合作趋势:扩大适应症以及推进到一二线治疗

出海授权合作中的风险控制、知识产权保护

资本视角:ADC药物投资方向

B2: 案例展示:创新ADC技术平台

全面革新ADC 设计:优化的抗体、可裂解的连接子、创新的毒素

设计链接器以增加ADC 功效和降低毒性

使用两种不同的双有效负载 ADC

细胞毒素可降低药物耐药性

新型ADC平台:负载多样化

B3: 授权出海及商业化策略

从PD-1授权出海中学到的经验与启示

建立更广泛的合作来扩展管线以及开拓海外市场

与海外监管单位保持密切沟通,携手合作方共同应对注册申报挑战

急剧增长的ADC销售份额共同应对海外市场商业化开发挑战

C1: 连接子 & 毒素 以及ADC的耐受性

通过接头设计: 提高功效、稳定性并减少脱靶毒性

 非内化的ADC开发

 ADC 毒性的影响和优化策略

 最小化毒性并提高耐受性, 以最大化 ADC 的治疗效果

 免疫原性、旁观者效应或系统性毒素以及快速清除

C2: 选择可靠的合作伙伴共同应对工艺挑战

 确保ADC的产品质量、效力

 稳健可放大的工艺、支持快速工艺转移

 如何协同小分子与大分子共同工艺优化的挑战

 抗体工程化、药物递送策略

 应对不同偶联ADC的下游高效纯化

 全球ADC外包市场、如何选择可靠的CDMO合作伙伴

C3; 质量控制及生物分析策略

 识别和研究新型偶联位点的快速表征分析

 推动CQA属性落地,迎接生产挑战

 解决ADC药物特殊的生物分析挑战

 复杂的结构对生物分析的影响

 与时俱进的生物分析工具

 ADC药物的质量控制和药代PK分析策略

中文官网

https://www.bagevent.com/event/adc2024

合作联系:

演讲联系人:Ada   18601610075   adaliu@chujietech.com

赞助联系人:Wilson  18662147488  wilsonwang@chujietech.com

EN Version

Event info:

Name:The 5th ADC Development Summit (China Focus)

Location: Beijing,China

Time: March 1-2,2024

Event Background:

As of October 30,2023, 15 ADC drugs had received approval worldwide.  Promising clinical benefits and significant advancements had been made by the effort from academic and industry since 2018.  For instance, Enhertu a groundbreaking treatment for HER2+ Cancer showing great potential to become blockbuster. The global ADC market in 2022 has grown to US$7.9 billion with a CAGR of 40.4% between 2018 and 2022. Innovation Conjugate platform, optimization of DASs and improved linker together improving ADC precision、clinical efficiency、reduced off-target toxicity。 China's ADC drug development has also successfully attracted investments, cooperation, and licensing out for big pharmaceuticals worldwide.  As for this background, we are going to launch the 5th ADC Development Summit in March 1-2, 2024. Beijing, China.  We are looking forward to meeting you onsite!

 

Event Logo:

image.png

Event Topics

Main Forum - Global ADC Investment and Cooperation

ADCs Taking Center Stage

Chinese Collaborations, Approvals and Expansions

The Drivers Behind the Demand for ADCs

A1: Target Selection and Preclinical Research

Novel Biomarkers in ADC

ADC Nonclinical Pharmacology, Toxicology Research and Safety Considerations

Regulatory Perspective of ADCNonclinical Safety Assessments

Validated, End-to-End ADC Discovery Platform

Evolving Strategies for Target Selection for ADC

A2: Clinical Development and Beyond Oncology

Global Clinical Trials Challenge

The Strategic Significance and Practice of Clinical Differentiation Development of ADC


ADC Combination Therapy: Combining with Chemotherapy

Exploring ADCs in Solid Tumor and Beyond Streamline the Clinical Path

A3: Next-Generation Conjugates Modalities

Emerging Different Types of Payloads with Novel Mechanism

Increasing Investment for XDC

Better Design and Bring XDC into Clinical


Emerging New Modality Degrader-Antibody Conjugates / Peptide Drug Conjugates / Dual-Site or Dual-Target ADCs / Bicycle Radio-Conjugates etc…

B1: Collaboration Between MNC & China Biotech

Wider Therapeutic Window Challenge

Development Progress and Collaborative Challenges Between MNC and Chinese Biotech

Global ADC Drug Development & China Opportunities

Next Cooperation Trend: Expansion of Applications and Treatment lines

Risk Management and Patent Protection

B2: Novel ADC Platform Showcase

Revolutionizing ADC Design: Optimized Antibodies, Cleavable Linkers, Innovative Payloads

Designing Linkers to Increase ADC Efficacy and Reduce Toxicity

Dual-Payload ADCs Using Two Different Cytotoxins to Reduce Resistance

Novel ADC Platform Payload Diversification

B3: License-out & Commercialization Strategy

Lessons Learned from PD-1 License-Out

Broad Collaborations to Expand Pipelines and Explore Overseas Opportunities

Together With Partner and Communicate with Regulatory Closely for IND Application

Jointly Respond to the Commercial Development of Overseas Markets

C1: Linker & Toxicities and ADC Tolerability

Improve Efficacy, Stability, and Reduce Off-Target Toxicities with Linker Design

Effects of ADC Toxicity and Optimization Strategies

Minimizing Toxicities & Improving Tolerability to Maximize the Tl of ADCs

Immunogenicity, Bystander or Systemic Toxicity, and Rapid Clearance

C2: Process Development with Reliable Partner

Ensuring Your ADC's Product Quality, Identity & Potency

Optimizing ADC Process Development to Deliver on Accelerated Timelines

Engineering, Delivery & Dosing Strategies

Diversification of ADC Formats and Overcoming Purification Challenges

C3: Quality Control and Bioanalytical Strategies

Bioanalytical Strategies for ADC PK Analysis

Rapid Characterization Methods to Identify and Investigate New Bioconjugation Sites

Manufacturing Challenges and Trends

Solving Unique ADC Bioanalytical Challenges State-of-the-art Bioanalytical Tools

Event Website:

Websitehttps://www.bagevent.com/event/ADC2024EN

Contact Us

Speak Opportunity:Ada   18601610075   adaliu@chujietech.com

Sponsor Opportunity:Wilson  18662147488  wilsonwang@chujietech.com


快速导航:
我要报名 联系我们

扫一扫

手机查看更方便